ArticleJACC. Case reports2025
Left Ventricular Dysfunction Caused by Combined Pembrolizumab and Lenvatinib Following Doxorubicin: Which Agent Is the Culprit?
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombination chemotherapy has improved cancer outcomes; however, identifying suspected cardiotoxic chemotherapies can be challenging when multiple chemotherapies are initiated simultaneously. CASE SUMMARY: A 58-year-old woman with endometrial cancer developed heart failure, with a reduced left ventricular ejection fraction of 26%, 10 months after combined pembrolizumab and lenvatinib after doxorubicin. Cardiac magnetic resonance revealed acute myocarditis. Endomyocardial biopsy revealed interstitial fibrosis and scattered CD3-positive T-lymphocyte infiltration without myocytic necrosis. After discontinuation of pembrolizumab and lenvatinib, left ventricular function recovered without steroids. Pembrolizumab monotherapy was resumed for lung metastasis. DISCUSSION: This case highlights the importance of identifying different cardiotoxic mechanisms. Potential causes of left ventricular dysfunction could overlap with immune checkpoint inhibitor-induced myocarditis from pembrolizumab and reversible cardiotoxicity from lenvatinib, based on myocardial fibrosis caused by doxorubicin cardiotoxicity. TAKE-HOME MESSAGE: Multidisciplinary discussions are crucial for identifying suspected cardiotoxic chemotherapy and exploring additional chemotherapy options, including rechallenging immune checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.